NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03588091,Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer,https://clinicaltrials.gov/study/NCT03588091,,UNKNOWN,"This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel versus placebo and trastuzumab plus docetaxel given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer.",NO,HER2-positive Breast Cancer,DRUG: Pyrotinib|DRUG: Placebo Oral Tablet|DRUG: Trastuzumab|DRUG: Docetaxel,"Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by independent review committee(IRC), through study completion, an average of 1 year","Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by sites, Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4,each cycle is 21 days)|Event-free survival(EFS), Following surgery until Year 3|Disease-free Survival (DFS), Following surgery until Year 3|Distance Disease-free Survival (DDFS), Following surgery until Year 3|Objective Response Rate (ORR) during neoadjuvant period, Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months",,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,355,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",HR-BLTN-III-NeoBC,2018-07-24,2021-04-30,2022-06,2018-07-17,,2021-08-04,"Peking University People's Hospital, Beijing, Beijing, 100044, China|The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, 100071, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China|Sun Yet-Sen University Cancer Center, Guangzhou, Guangdong, 510010, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510289, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China|The affiliated cancer hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, 450000, China|Huai'an First People's Hospital, Huaian, Jiangsu, 223001, China|JiangSu Province Hospital, Nanjing, Jiangsu, 210029, China|Shandong Cancer Hospital, Jinan, Shandong, 250000, China|The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, 266100, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|The Second Affiliated Hospital Of Xi'an Jiaotong University, Xian, Shanxi, 710004, China|The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310005, China|The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China",
